Theα2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type

The mixedα1/α2 adrenoceptor agonist clonidine has been shown by us previously to impair certain attentional and executive functions in healthy volunteers. The present investigation examines the effects of theα2 adrenoceptor antagonist idazoxan (IDZ) on cognitive function in patients with dementia of frontal type (DFT). Using a placebo-controlled ABBA design, three DFT patients were given two doses of IDZ and tested on a range of computerised tests of attention, memory and executive function. Idazoxan was found to produce dose-dependent improvements in performance, particularly on tests of planning, sustained attention, verbal fluency and episodic memory. In contrast, IDZ produced deficits in performance on a test of spatial working memory. These results suggest that IDZ may be useful as a putative cognitive enhancer, particularly in patients showing a specific pattern of frontal lobe dysfunction.

[1]  P. Francis,et al.  Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. , 1993, Dementia.

[2]  B. Sahakian,et al.  Clonidine-induced changes in the spectral distribution of heart rate variability correlate with performance on a test of sustained attention , 1994, Journal of psychopharmacology.

[3]  C. Carter,et al.  Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. , 1987, The Journal of pharmacology and experimental therapeutics.

[4]  R. Delanoy,et al.  Locus coeruleus stimulation decreases deoxyglucose uptake in ipsilateral mouse cerebral cortex , 1979, Brain Research.

[5]  R. Mair,et al.  Cognitive enhancement in Korsakoff's psychosis by clonidine: A comparison with l-Dopa and Ephedrine , 2004, Psychopharmacology.

[6]  L. Stein,et al.  Memory enhancement by central administration of norepinephrine , 1975, Brain Research.

[7]  D. Nutt,et al.  The effects and after effects of the α2-adrenoceptor antagonist idazoxan on mood, memory and attention in normal volunteers , 1992, Journal of psychopharmacology.

[8]  B. Sahakian,et al.  Contrasting effects of clonidine and diazepam on tests of working memory and planning , 1995, Psychopharmacology.

[9]  G. Aston-Jones,et al.  Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. , 1991, Progress in brain research.

[10]  T. Robbins,et al.  Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man , 1991, Neuropsychologia.

[11]  Adrian M. Owen,et al.  Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man , 1995, Neuropsychologia.

[12]  A. Sahgal.  Some limitations of indices derived from signal detection theory: evaluation of an alternative index for measuring bias in memory tasks , 2004, Psychopharmacology.

[13]  J Risberg,et al.  Neuropsychological findings in frontal lobe dementia. , 1993, Dementia.

[14]  A. Roach,et al.  Studies on RX 781094: a selective, potent and specific antagonist of α2‐adrenoceptors , 1983 .

[15]  B. Sahakian,et al.  Clonidine and diazepam have differential effects on tests of attention and learning , 1995, Psychopharmacology.

[16]  Peter La Cour,et al.  Rivermead Behavioural Memory Test , 1990 .

[17]  C. McDougle,et al.  Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine , 2005, Psychopharmacology.

[18]  Functional imaging, the frontal lobes, and dementia. , 1998, Dementia.

[19]  T. Robbins,et al.  Cortical noradrenaline, attention and arousal , 1984, Psychological Medicine.

[20]  T. Shallice,et al.  Frontal lesions and sustained attention , 1987, Neuropsychologia.

[21]  D. Neary.  Dementia of Frontal Lobe Type , 1990, Journal of the American Geriatrics Society.

[22]  P. Tariot,et al.  Pharmacologic modelling of Alzheimer's disease , 1986, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[23]  A. C. Roberts,et al.  Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: Evidence for a specific attentional dysfunction , 1989, Neuropsychologia.

[24]  T. Robbins,et al.  A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. , 1988, Brain : a journal of neurology.

[25]  P. Cowen,et al.  Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects , 1991, Journal of psychopharmacology.

[26]  T. Shallice.  Specific impairments of planning. , 1982, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[27]  A. Arnsten,et al.  Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: Indirect effects of yohimbine versus direct effects of clonidine , 1993, Neurobiology of Aging.

[28]  Roberta F. White,et al.  The diagnostic utility of savings scores: differentiating Alzheimer's and Huntington's diseases with the logical memory and visual reproduction tests. , 1993, Journal of clinical and experimental neuropsychology.

[29]  L. Gustafson,et al.  Clinical picture of frontal lobe degeneration of non-Alzheimer type. , 1993, Dementia.

[30]  T. Robbins,et al.  Detection of visual memory and learning deficits in Alzheimer's disease using the Cambridge neuropsychological test automated battery , 1991 .

[31]  M. Gallagher,et al.  Memory formation: evidence for a specific neurochemical system in the amygdala. , 1977, Science.

[32]  B. Sahakian,et al.  Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in alzheimer's disease , 2005, Psychopharmacology.

[33]  B. Sahakian,et al.  The Effects of Nicotine on Attention, Information Processing, and Short-Term Memory in Patients with Dementia of the Alzheimer Type , 1989, British Journal of Psychiatry.

[34]  R. Fields,et al.  Clonidine improves memory function in schizophrenia independently from change in psychosis Preliminary findings , 1988, Schizophrenia Research.

[35]  S. Z. Langer,et al.  Recent Developments In Noradrenergic Neurotransmission and its Relevance to the Mechanism of Action of Certain Antihypertensive Agents , 1980, Hypertension.

[36]  William E. Semple,et al.  Functional localization of sustained attention: Comparison to sensory stimulation in the absence of instruction , 1988 .

[37]  P. Liddle.  Schizophrenic syndromes, cognitive performance and neurological dysfunction , 1987, Psychological Medicine.

[38]  J. Hodges,et al.  Dementia of frontal type and the focal lobar atrophies , 1993 .

[39]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[40]  M. Dontenwill,et al.  The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. , 1989, European journal of pharmacology.

[41]  P. Goldman-Rakic,et al.  Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. , 1985, Science.

[42]  P. Tariot,et al.  Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls. , 1985, Psychopharmacology bulletin.

[43]  A M Owen,et al.  Double dissociations of memory and executive functions in working memory tasks following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. , 1996, Brain : a journal of neurology.

[44]  L. Finch,et al.  The α1- and α2-adrenoceptor involvement in the central cardiovascular action of clonidine in the conscious renal hypertensive cat , 1982 .

[45]  D. Neary,et al.  Dementia of frontal lobe type. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[46]  D L Woods,et al.  Electrophysiologic evidence of increased distractibility after dorsolateral prefrontal lesions , 1986, Neurology.

[47]  Keith Wesnes,et al.  Effects of scopolamine and nicotine on human rapid information processing performance , 2004, Psychopharmacology.

[48]  B. Sahakian,et al.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB , 2005, Psychopharmacology.

[49]  T. Su,et al.  Idazoxan, an ??2 Antagonist, Augments Fluphenazine in: Schizophrenic Patients , 1993 .

[50]  Don McNicol,et al.  A Primer of Signal Detection Theory , 1976 .

[51]  Arthur L. Benton,et al.  Differential behavioral effects in frontal lobe disease , 1968 .

[52]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[53]  B. Sahakian,et al.  Cholinergic effects on constructional abilities and on mnemonic processes: a case report , 1987, Psychological Medicine.

[54]  M. Loeb,et al.  The Psychology of Vigilance , 1982 .

[55]  C. Frith,et al.  The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action , 1987, Psychological Medicine.

[56]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[57]  C R Jack,et al.  MRI hippocampal volumes and memory function before and after temporal lobectomy , 1993, Neurology.

[58]  G. Vauquelin,et al.  Imidazoline receptors, non-adrenergic idazoxan binding sites and α2-adrenoceptors in the human central nervous system , 1994, Neuroscience.

[59]  T. Robbins,et al.  Planning and spatial working memory following frontal lobe lesions in man , 1990, Neuropsychologia.